Replies to post #8224 on BioCurex, Inc.(fka BOCX)

[Gold Seeker]

This cancer marker would be a genetic test so it will remain with Abbott at their molecular division. It is also another semi exclusive agreement as with BioCurex. Another marker that I previously posted about was PCA3. It is also a genetic marker. Both of the tests would be expensive, probably in the range of several hundred dollars. The PCA3 test requires manually massaging the prostate during the urine collection process and that would be done with the INDEX finger. The good part, I guess, would be running both tests with the same sample collection.

http://www.prostate-cancer.org/education/preclin/Torres_PCA3.html